From: Cost-effectiveness of edaravone dexborneol versus human urinary kallidinogenase for acute ischemic stroke in China
EDB
HUK
QALYs
7.621
7.468
Costs
¥28,687
¥27,832
Drug costs
¥2,772
¥2,100
Hospitalization costs
¥18,116
¥18,005
Post-stroke costs
¥7,799
¥7,727
NMB
¥588,426
¥576,927
Incremental costs
¥856
Incremental QALYs
0.153
Incremental NMB
¥11,499
ICER
¥5,608